2023 World Conference on Lung Cancer (Posters)-EP07.01. Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care

EP07.01. Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care - PDF(Abstract)

Back to course

Pdf Summary

This session at WCLC 2023 presented a study on lead-time bias in surgically resected non-small cell lung cancer (NSCLC) diagnosed through different pathways of care. The study compared the survival rates of stage I NSCLC patients in a population-based surgical resection cohort from 2015 to 2022, categorized according to diagnosis through low-dose CT lung cancer screening (LDCT), Lung Nodule Programs (LNP), or non-program-based (NPB) pathways.<br /><br />The researchers found that of the 1800 patients, 116 (6.4%) were diagnosed through LDCT, 378 (21%) through LNP, and 1306 (72.6%) through NPB. Comparisons across the pathways showed differences in patient characteristics, with varying proportions of race, gender, age, smoking history, comorbidity score, and tumor characteristics.<br /><br />The 5-year survival rates for the overall cohort were 92% for LDCT-diagnosed NSCLC, 77% for LNP-diagnosed NSCLC, and 69% for NPB-diagnosed NSCLC. When analyzing patients with pathologic stage I NSCLC, the 5-year survival rates were 96% for LDCT, 78% for LNP, and 78% for NPB.<br /><br />The study concluded that unlike LDCT-diagnosed NSCLC, there was no evidence of lead-time bias in NSCLC diagnosed through LNP. This suggests that implementing Lung Nodule Programs could potentially lead to a significant reduction in population-level mortality. The researchers called for further rigorous prospective studies to validate these findings.<br /><br />Overall, this study highlights the importance of different pathways of care in the diagnosis and treatment of early-stage NSCLC and the potential benefits of implementing Lung Nodule Programs.

Asset Subtitle

Raymond Osarogiagbon

Meta Tag

Speaker Raymond Osarogiagbon

Topic Early-Stage NSCLC: Best Practice

Keywords

WCLC 2023

lead-time bias

surgically resected

non-small cell lung cancer

NSCLC

low-dose CT lung cancer screening

Lung Nodule Programs

non-program-based

patient characteristics

5-year survival rates